Company: MDCXW
Filing Date: 2025-09-02
Form Type: 8-K
Source: 0001062993-25-015149
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-02
Form: 8-K
Item: Item 3.02
Chunk 2
---
 sold 100,000 of its common shares (the "Common Shares") to Yorkville for $2.0396 per share, or $203,960 in consideration and 150,000 Common Shares to Yorkville for $1.9105 per share, or $286,575 in consideration, respectively (together, the "SEPA Advances"). The Company sold, in the aggregate, 250,000 Common Shares to Yorkville through the SEPA Advances and received aggregate net proceeds of approximately $490,535. The Company may cause Yorkville to purchase additional Common Shares under the SEPA from time to time, subject to the satisfaction or waiver of the conditions and limitations set forth in the SEPA. The Company intends to use part of the net proceeds from the SEPA Advances to prepay a portion of the debentures the Company has outstanding with Yorkville, as described in that certain Current Report on Form 8-K dated June 20, 2025. The Common Shares were issued and sold to Yorkville in reliance upon the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act. The Company is relying on this exemption from registration based in part on representations made by Yorkville in the SEPA. Yorkville may resell the Common Shares it has purchased from the Company under the SEPA from time to time pursuant to that certain effective registration statement on form S-1 (File No. 333-287582), which has been filed by the Company in accordance with its requirements under the SEPA.

This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 29, 2025, pursuant to Section 11.8 of the Definitive Agreement, the board of directors of the Company (the "Board") appointed Patrick J. Mahaffy, the former chairman of Antev, to serve on the Board until the Company's 2026 annual meeting of shareholders or until his successor is duly elected or appointed, thereby increasing the number of directors on the Board to nine. Mr. Mahaffy was not appointed to serve on